Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015, 159(4):562-568 | DOI: 10.5507/bp.2015.033

Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris

Marketa Husakovaa, Jan Lippertb, Jiri Stolfaa, Liliana Sedovaa, Petr Arenbergerc, Zdenka Lacinovad, Karel Pavelkaa
a Institute of Rheumatology, Na Slupi 4, 12850 Prague 2, Czech Republic
b Department of Dermatology, Stadt. Klinikum Gorlitz, Girbingsdorfer Strasse 1-3, Gorlitz, Germany
c The Clinic of Dermatology and Venereology, 3rd Faculty of Medicine, Charles University in Prague and Faculty Hospital of Kralovske Vinohrady, Prague
d 3rd Department of Internal Medicine - Department of Endocrinology and Metabolism, 1st Faculty of Medicine, Charles University in Prague and General University Hospital in Prague

Background and Aims: Psoriasis vulgaris (PV) is complicated in up to 40% patients by the inflammatory joint disease psoriatic arthritis (PsA). Neither the aetiology of the arthritis nor specific laboratory markers for its disease activity have been clearly elucidated. Prolactin (PRL) acts as a cytokine with immunomodulatory functions and plays a role in skin and joint biology. The results on PRL however as a marker are unclear. The aim of this study was to confirm whether serum PRL levels reflect systemic complications of PV, like inflammatory joint disease and/or can serve as a marker of disease activity in both cases.

Methods: A total of 70 patients with PV without arthritis and 40 patients suffering from PsA were included. In all patients, we determined skin disease activity according to the PASI index and in PsA, active disease assessed as swollen or tender joints. The control group included 27 age and sex matched healthy individuals. The concentration of PRL in the serum was measured by immunoradiometric assays.

Results: The PRL serum levels were significantly increased in PsA patients (299.2±28.29 mIU/L) compared to PV only patients (201.4.2±11.72 mIU/L), P = 0.0003 and healthy individuals (198.2±15.31 mIU/L), P = 0.007. The serum PRL levels in PsA with active disease 336.8±42.50 (mIU/L) were higher than in PV and controls, P < 0.0001 and P = 0.002 respectively. In PV only patients, there was no correlation between PASI and PRL levels.

Conclusion: Our results showed that PRL serum levels are a marker of active arthritis in PsA and reflects systemic complication rather than local skin activity.

Keywords: prolactin, serum levels, psoriasis vulgaris, psoriatic arthritis, arthritis, immune cells

Received: January 13, 2015; Accepted: June 26, 2015; Prepublished online: July 10, 2015; Published: December 3, 2015  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Husakova, M., Lippert, J., Stolfa, J., Sedova, L., Arenberger, P., Lacinova, Z., & Pavelka, K. (2015). Elevated serum prolactin levels as a marker of inflammatory arthritis in psoriasis vulgaris. Biomedical papers159(4), 562-568. doi: 10.5507/bp.2015.033
Download citation

References

  1. Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schäfer I. Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. Br J Dermatol 2011;165(4):865-73. Go to original source... Go to PubMed...
  2. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, Rolstad T, Margolis DJ. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005;52(1):23-6. Go to original source... Go to PubMed...
  3. Kanai Y, Satoh T, Igawa K, Yokozeki H. Impaired expression of Tim-3 on Th17 and Th1 cells in psoriasis. Acta Derm Venereol 2012;92(4):367-71. Go to original source... Go to PubMed...
  4. Tonel G, Conrad C. Interplay between keratinocytes and immune cells - recent insights into psoriasis pathogenesis. Int J Biochem Cell Biol 2009;41(5):963-8. Go to original source... Go to PubMed...
  5. Khraishi M, Chouela E, Bejar M, Landells I, Hewhook T, Rampakakis E, Sampalis JS, Abouchehade K. High prevance of psoriatic arthritis in a cohort of patients with psoriasis seen in a dermatology practice. J Cutan Med Surg 2012;16(2):122-7. Go to original source... Go to PubMed...
  6. Eder L, Chandran V, Shen H, Cook RJ, Shanmugarajah S, Rosen CF, Gladman DD. Incidence of arthritis in a prospective cohort of psoriasis patients. Arthritis Care Res (Hoboken) 2011;63(4):619-22. Go to original source... Go to PubMed...
  7. Elkayam O, Ophir J, Yaron M, Caspi D. Psoriatic arthritis: interrelationships between skin and joint manifestations related to onset, course and distribution. Clin Rheumatol 2000;19(4):301-5. Go to original source... Go to PubMed...
  8. Langenbruch A, Radtke MA, Krensel M, Jacobi A, reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol 2014;141(5):1123-8. Go to original source... Go to PubMed...
  9. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3(1):55-78. Go to original source... Go to PubMed...
  10. Nossent JC, Gran JT. Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway. Scan J Rheumatol 2009;38(4):251-5. Go to original source... Go to PubMed...
  11. Mease P. Psoriatic arthritis and spondyloarthritis assessment and management update. Curr Opin Rheumatol 2013;25(3):287-96. Go to original source... Go to PubMed...
  12. Vandooren B, Noordenbos T, Ambarus C,c Krausz S, Cantaert T, Yeremenko N, Boumans M, Lutter R, Tak PP, Baeten D. Absence of a classically activated macrophage cytosine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum 2009;60(4):966-75. Go to original source... Go to PubMed...
  13. Suzuki E, Mellins ED, Gershwin ME, Nestle FO, Adamopoulos IE. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev 2014;13(4-5):496-502. Go to original source... Go to PubMed...
  14. Hebert HL, Ali FR, Bowes J, Griffiths CE, Barton A, Warren RB. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. Br J Dermatol 2012;166(3):474-82. Go to original source... Go to PubMed...
  15. Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Navarro C. Prolactin and autoimmunity. Clin Rev Allerg Immunol 2011;40(1):50-9. Go to original source...
  16. Costanza M, Binart N, Steinman L, Pedotti R. Prolactin: A versatile regulator of inflammation and autoimmune pathology. Autoimmun Rev 2015;14(3):223-30. Go to original source... Go to PubMed...
  17. Kanda N, Shibata S, Tada Y, Nashiro K, Tamaki K, Watanabe S. Prolactin enhances basal and IL-17 induced CCL20 production by human keratinocytes. Eur J Immunol 2009;39(4):996-1006. Go to original source... Go to PubMed...
  18. Kanda N, Watanabe S. Prolactin enhances interferon-g-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes. Endocrinology 2007;148(5):2317-25. Go to original source... Go to PubMed...
  19. Hau CS, Kanda N, Tada Y, Shibata S, Sato S, Watanabe S. Prolactin induces the production of Th17 and Th1 cytokines/chemokines in murine Imiquimod-induces psoriasiform skin. J Eur Acad Dermatol Venereol 2014;28(10):1370-9 Go to original source... Go to PubMed...
  20. El.-Khateeb EA, Zuel-Fakkar NM, Eid SM, Abdul-Wahab SE. Prolactin level is significantly elevated in lesional skin patients with psoriasis. Int J Dermatol 2011;50(6):693-6. Go to original source... Go to PubMed...
  21. Dilme-Carreras E, Martin-Ezquerry G, Sanchez-Regana M, Umbert-Millet P. Serum prolactin levels in psoriasis and correlation with cutaneous disease activity. Clin Exp Dermatol 2011;36(1):29-32. Go to original source... Go to PubMed...
  22. McMurray RW. Bromocriptine in rheumatic and autoimmune diseases. Semin Arthritis Rheum 2001;31(1):21-32. Go to original source... Go to PubMed...
  23. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157(4):238-44. Go to original source... Go to PubMed...
  24. Peeva E, Zouali M. Spotlight on the role of hormonal factors in the emergence of autoreactive B-lymphocytes. Immunol Lett 2005;101(2):123-43. Go to original source... Go to PubMed...
  25. Saha S, Gonzalez J, Rosenfeld G, Keiser H, Peeva E. Prolactin alters the mechanisms of B cells tolerance induction. Arthritis Rheum 2009;60(6):1743-52. Go to original source... Go to PubMed...
  26. Boyd AS, Morris LF, Phillips CM, Menter MA. Psoriasis and pregnancy: hormone and immune system interaction. Int J Dermatol 1996;35(3):169-72. Go to original source... Go to PubMed...
  27. Murase JE, Chan KK, Garite TJ, CooperDM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol 2005;141(5):601-6. Go to original source... Go to PubMed...
  28. Sanchez Regana M, Umbert Millet P. Psoriasis in association with prolactinoma: three cases. Br J Dermatol 2000;143(4):864-7. Go to original source... Go to PubMed...
  29. Giasuddin AS, El-Sherif AI, El-Ojali SI. Prolactin: does it have a role in the pathogenesis of psoriasis? Dermatology 1998;197(2):119-22. Go to original source... Go to PubMed...
  30. Hegman M, Nilson D, De la Torre B. Low blood and synovial fluid levels of sulpho-conjugated steroids in rheumatoid arthritis. Clin Exp Rheumatol 1992;10(1):25-30. Go to PubMed...
  31. Eulry F, Mayudon H, Lechevalier D, Bauduceau B, Ariche L, Ouakil H, Crozes P, Magnin J. Treatment of rheumatoid psoriasis with bromocriptine. Presse Med 1995;24(35):1642-4. Go to PubMed...
  32. Buskila D, Sukenik S, Holcberg G, Horowitz J. Improvement of psoriatic arthritis in a patiens treated with bromocriptine for hyperprolactinaemia. J Rheumatol 1991;18(4):611-2. Go to PubMed...
  33. Malligarjunan H, Gnanaraj P, Subramanian S, Elango T, Daylan H. Clinical Efficacy of propylthiouracil and its influence on prolactin in psoriatic patients. Clin Biochem 2011;44(14-15):1209-13. Go to original source... Go to PubMed...
  34. Handjani F, Saki N, Ahrari I, Ebrahimi M, Khorrami MM, Nematollahi P. Serum prolactin levels in psoriasis vulgaris. ISRN Dermatol 2014 [serial on the Internet] Feb 23;2014:586049.doi: 10.1155/2014/586049 Go to original source...
  35. Robati RM, Toossi P, Rahmati-Roodsari M, Khalilayar S, Abolhasani E, Namayi N, Zounespour S. Association of psoriasis Severin with serum prolactin, thyroid hormones, and cortisol before and after treatment. ScientificWorldJournal 2013 [serial on the Internet] Oct 28;2013:921819. doi: 10.1155/2013/921819. eCollection 2013 Go to original source...
  36. Tomei F, Ciarrocca M, Cherubini E, Rosati MV, Monti C, Capozzela A, Tomei G. Prolactin levels in workers exposed to chemical, physical and psycho-social urban stressors. J Occup Health 2006;48(4):235-60. Go to original source... Go to PubMed...
  37. Daza L, Martin-Jimenez R, Del la Torre PX, Hernandez E, Murillo B. Improvement of ACTH response to insulin tolerance test in female patients with rheumatoid arthritis due to tumor necrosis factor inhibition. Eur J Endocrinol 2007;157(1):47-51. Go to original source... Go to PubMed...
  38. Kreiner FF, Galbo H. Activity of the neuroendocrine axes in patients with polymyalgia rheumatic before and after TNF-α blocking etanercept treatment. Arthritis Res Ther 2012;14(4):R186. Go to original source... Go to PubMed...
  39. Eijsbouts AM, van den Hoogen FH, Laan RF, Sweep CG, Hermus AR, can de Putte LB. Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis? Correlation with the disease activity. Ann Rheum Dis 2005;64(3):433-7. Go to original source... Go to PubMed...
  40. Rovensky J, Imrich R, Malis F, Zlnay M, Macho L, Koska J, Vigas M. Prolactin and growth hormone responses to hypoglycemia in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2004;31(12):2418-21. Go to PubMed...
  41. Girolomoni G, Philips JT, Bergstresser PR. Prolactin stimulates proliferation of cultured human keratinocytes. J Invest Dermatol 1993;101(3):275-9. Go to original source... Go to PubMed...
  42. McGonagle D, Ash Y, Dickie L, McDermott M, Azdin SZ. The early phase of psoriatic arthritis. Ann Rheum Dis 2011;70(S1):i71-6. Go to original source... Go to PubMed...
  43. Fitzgerald O, Chandran V. Update on biomarkers in psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol 2012;39(2):427-30. Go to original source... Go to PubMed...
  44. Pedersen SJ, Hetland ML, Sorensen IJ, Ostergaard M, Nielsen HJ, Johansen JS. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNF-α inhibitors. Clin Rheumatol 2010;29(11):1301-9. Go to original source... Go to PubMed...
  45. Gerez J, Bonfiglio J, Sosa S, Giacomini D, Acuna M, Nagashima AC, Perone MJ, Silberstein S, Renner U, Stalla GK, Arzt E. Molecular transduction mechanisms of cytokine -hormone interactions: role of gp130 cytokines. Exp Physiol 2007;92(5):801-6. Go to original source... Go to PubMed...
  46. Tang C, Li Y, Lin X, Ye J, Li W, He Z, Li F, Cai X. Prolactin increases tumor necrosis factor alpha expression in peripheral CD 14 monocytes of patients with rheumatoid arthritis. Cell Immunol 2014;290(1):164-8. Go to original source... Go to PubMed...